382 related articles for article (PubMed ID: 26654098)
1. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
[TBL] [Abstract][Full Text] [Related]
2. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
3. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
4. The role of gamma delta T cells in haematopoietic stem cell transplantation.
Minculescu L; Sengeløv H
Scand J Immunol; 2015 Jun; 81(6):459-68. PubMed ID: 25753378
[TBL] [Abstract][Full Text] [Related]
5. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
Zaghi E; Calvi M; Di Vito C; Mavilio D
Front Immunol; 2019; 10():2794. PubMed ID: 31849972
[TBL] [Abstract][Full Text] [Related]
6. Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis.
Arruda LCM; Gaballa A; Uhlin M
Blood Adv; 2019 Nov; 3(21):3436-3448. PubMed ID: 31714966
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
9. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation.
Song Y; Zhu Y; Hu B; Liu Y; Lin D; Jin Z; Yin Z; Dong C; Wu D; Liu H
Front Immunol; 2020; 11():558143. PubMed ID: 33178187
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
11. The Role of γδ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges.
Janssen A; van Diest E; Vyborova A; Schrier L; Bruns A; Sebestyen Z; Straetemans T; de Witte M; Kuball J
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062321
[TBL] [Abstract][Full Text] [Related]
12. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Fu J; Heinrichs J; Yu XZ
Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):277-301. PubMed ID: 24699629
[TBL] [Abstract][Full Text] [Related]
13. Unconventional T Cells Influence Clinical Outcome After Allogeneic Hematopoietic Cell Transplantation.
Siblany L; Stocker N; Ricard L; Brissot E; Duléry R; Banet A; Sestili S; Belhocine R; Van de Wyngaert Z; Bonnin A; Capes A; Ledraa T; Beurier P; Fadel K; Mohty M; Gaugler B; Malard F
J Clin Immunol; 2024 Jun; 44(6):139. PubMed ID: 38822857
[TBL] [Abstract][Full Text] [Related]
14. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Locatelli F; Merli P; Rutella S
J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
[TBL] [Abstract][Full Text] [Related]
15. Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI.
Xu L; Weng J; Huang X; Zeng C; Chen S; Geng S; Yang L; Wu S; Huang S; Du X; Li Y
Oncotarget; 2016 Jul; 7(28):42943-42952. PubMed ID: 27356746
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
17. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
18. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
19. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
Jiang H; Fu D; Bidgoli A; Paczesny S
Front Immunol; 2021; 12():761448. PubMed ID: 34675938
[TBL] [Abstract][Full Text] [Related]
20. Dendritic Cells Are Critical for the Activation and Expansion of Vδ2
Wang X; Liu J; Gao H; Mo XD; Han T; Xu LP; Zhang XH; Huang XJ
Front Immunol; 2018; 9():2528. PubMed ID: 30443256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]